EMEA-001030-PIP01-10-M09
Key facts
| Invented name |
Invokana
|
| Active substance |
canagliflozin
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0268/2021
|
| PIP number |
EMEA-001030-PIP01-10-M09
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
Tel. +32 14602111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|